CAR-T therapy international logistics

What this drug class is

Autologous CAR-T involves leukapheresis, cryogenic transport in dry-shipper dewars, a manufacturing slot, and a return shipment; almost no country imports it as a named-patient drug. This guide is for patients, families and treating physicians evaluating cross-border access in this category, who want a plain-language map of the supply chain, the regulatory exposure and the realistic cost envelope.

Clinical and handling profile

The handling profile drives most of the procurement architecture. Room-temperature oral agents ship by air with minimal customs friction. Refrigerated 2-8C biologics need validated containers and temperature loggers, and arrive with a hospital-pharmacy hand-off, not direct-to-patient. Cryogenic agents move in dry-shipper dewars on tightly scheduled corridors and require pre-cleared customs lanes. Live-cell autologous products are essentially non-shippable as named-patient drugs; the patient travels to the manufacturer or its certified treatment centre.

Country-by-country availability

Most novel drugs in this class are first launched in the US, EU and Japan, with the rest of the world following over 2-5 years. UAE and KSA are the fastest emerging-market jurisdictions in this category; India follows closely on small molecules and trails on cell therapies; Egypt and Pakistan trail further. The named-patient route exists in all of these for at least a subset of the class, but the documentation burden is heaviest in jurisdictions where the drug has no commercial registration.

Cost envelope

US WAC in this class typically runs 1.5-4x international list prices. Even when international list is available, named-patient supply often runs 10-25 percent above international list because the supply chain is patient-specific and the volume is single-unit. Patients should plan for a cost band, not a point estimate, and should not expect a meaningful discount on a single-cycle or single-infusion product.

Specific procurement notes

Manufacturer-direct supply, where available, is the cleanest route: shortest chain-of-custody, full provenance, and the manufacturer's own cold-chain. Specialty-pharmacy procurement is the most common route and is operationally similar; the difference is that the chain-of-custody passes through a US-licensed pharmacy. Hospital-led procurement is the slowest but is required in jurisdictions where the regulator only recognises a hospital pharmacy as the legal importer.

Risks and failure modes

Three failure modes dominate. First, a cold-chain excursion: a temperature logger flags a brief excursion outside specification, and the receiving physician declines the dose. Second, a customs hold: the broker did not pre-clear the regulator licence, and the drug sits at the port for 5-10 days, sometimes exceeding the stability window. Third, an eligibility miss: the patient does not meet the manufacturer's REMS or label criteria at administration, and the dose cannot be used. All three are addressed by upstream coordination, not by the procurement contract.

What patients should ask

Patients should ask the operator how the drug is shipped, what temperature loggers and seals are used, what happens on a cold-chain excursion, who pays for replacement on an excursion, and what the typical port-clearance time is in the destination country. They should ask the treating physician about REMS, monitoring requirements, and the post-administration follow-up schedule. They should not buy a drug in this class without a confirmed treating-physician administration plan.

How Reserve Meds handles this class

For this class, Reserve Meds will not ship direct-to-patient. The drug routes from a US-licensed specialty pharmacy, through a validated cold-chain carrier, to a treating physician or a hospital pharmacy at the destination, with the full DSCSA chain-of-custody and a temperature-logger report attached to the hand-off. We coordinate the pre-clearance with the destination regulator and the local customs broker. The patient never receives the drug at a home address.

Frequently asked questions

Will the drug arrive cold?

Cold-chain biologics ship in validated containers with temperature loggers; on arrival the logger and seals are reviewed before the hand-off to the treating physician.

Are biosimilars as good as the originator?

Regulators that have approved a biosimilar have already concluded clinical equivalence; the treating physician decides whether to interchange in any given patient.

What if the drug requires REMS?

REMS drugs require a US-licensed prescriber, a certified pharmacy, and patient enrollment; cross-border shipment is possible but the chain-of-custody is tighter.

Related on Reserve Meds

• Drug catalog
• Conditions
• Access pathways
• Countries
• Access guides
• Cold-chain basics
• CAR-T therapies in NPP
• Gene therapy access

Sources

• FDA - Cellular and Gene Therapy Products
• FDA - Biosimilars
• WHO - Essential medicines list
• EMA - Advanced therapy medicinal products

Start a request

Start a request